Insulin-like growth factor (IGF)-I, IGF-II and IGF-binding protein (IGFBP)-3 levels in Arab subjects with coronary heart disease

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 67, Issue 5, 2007, Pages 553-559

  Akanji, A O ^a   Suresh, C G ^c   Al Radwan, R ^a   Fatania, H R ^b  

^a KUWAIT UNIVERSITY   (Kuwait)

^b MUBARAK AL KABEER HOSPITAL   (Kuwait)

^c Central Blood Bank ^*  (Kuwait)

Author keywords

Arabs; Coronary heart disease; IGF I; IGF II; IGFBP 3; Insulin resistance

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO;

ADULT; ARABS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CORONARY DISEASE; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; KUWAIT; LIPOPROTEINS; MALE; MIDDLE AGED;

EID: 34548305037     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510601173153     Document Type: Article

References (21)

1. Holly J. Physiology of the IGF system. Novartis Foundation Symp 2004;262:19-35.
2. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002;23:824-54.
3. Frystyk J, Ledet T, Moller N, Flyvbjerg A, Orskov H. Cardiovascular disease and insulin-like growth factor I. Circulation 2002;106:893-5.
4. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease. A population-based case-control study. Circulation 2002;106:939-44.
5. Kaplan RC, Strickler HD, Rohan TE, Muzumdar R, Brown DL. Insulin-like growth factors and coronary heart disease. Cardiol Rev 2005;13:35-9.
6. Janssen JA, Lamberts SWJ. The role of IGF-I in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention possible? Eur J Endocrinol 2002;146:467-77.
7. Fischer F, Schulte H, Mohan S, Tataru M-C, Kohler E, Assmann G, et al. Associations of insulin-like growth factors, insulin-like growth factor binding proteins and acid-labile subunit with coronary heart disease. Clin Endocrinol 2004;61:595-602.
8. Ruotolo G, Bavenholm P, Brismar K, Efendic S, Ericsson CG, de Faire U, et al. Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment. J Am Coll Cardiol 2000;35:647-54.
9. Colangelo LA, Liu K, Gapstur SM. Insulin-like growth factor-1, insulin-like growth factor binding protein-3 and cardiovascular disease risk factors in young black men and white men. The CARDIA male hormone study. Am J Epidemiol 2004;160:750-7.
10. Alwan AA. Cardiovascular diseases in the eastern Mediterranean region. World Hlth Stat Q 1993;46:97-100.
11. Akanji AO, Al-Sulaiman A, Prabha K, Safar F, Al-Zaid K, Mojiminiyi OA. Profile of hyperlipidaemic patients in Kuwait: frequency of cardiovascular disease risk factors at presentation and initial response to treatment. J Kuwait Med Assoc 1997;29:25-33.
12. Akanji AO. Apo (a) isoforms do not predict coronary heart disease risk in a Gulf Arab population. Ann Clin Biochem 2000;37:360-6.
13. Anonymous . Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001;285:2486-97.
14. Alberti KGMM, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-62.
15. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
16. Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab 2003;17:302-22.
17. Conti E, Andreotti F, Sciahbasi A, Riccardi P, Marra G, Menini E, et al. Markedly reduced insulin-like growth factor-1 in the acute phase of myocardial infarction. J Am Coll Cardiol 2001;38:26-32.
18. Friberg L, Werner S, Eggertsen G, Ahnve G. Growth hormone and insulin-like growth factor-1 in acute myocardial infarction. Eur Heart J 2000;21:1547-54.
19. Spallarosa P, Brunelli C, Minuto F, Caruso D, Battistini M, Caponnetto S, et al. Insulin-like growth factor-1 and angiographically documented coronary artery disease. Am J Cardiol 1996;77:200-2.
20. Conti E, Carrozza C, Capoluongo E, Volpe M, Crea F, Zuppi C, et al. Insulin-like growth factor-1 as a vascular protective factor. Circulation 2004;110:2260-5.
21. Heald A, Kaushal K, Anderson S, Redpath M, Durrington PN, Selby PL, et al. Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk. Gynecol Endocrinol 2005;20:176-82.